Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%

Benchmarks Nifty23,440.80387.71FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return9.02 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return18.55 % Invest NowEnter search text:

The Economic Times daily newspaper is available online now. Read Today's Paper Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%ET OnlineLast Updated: Nov 02, 2026, 05:27:00 PM ISTSynopsis

Wockhardt has expanded its marketing access for Miqnaf in India following the removal of a supply condition. The company's biotechnology sector recorded significant revenue growth, indicating strong demand for its products. Zaynich received US FDA approval for complicated urinary tract infections, serving as a milestone for Indian pharmaceuticals.

Wockhardt has expanded marketing access to its novel antibiotic Miqnaf (nafithromycin) in India after the Drugs Controller General of India (DCGI) removed a supply condition, the company said in its second-quarter earnings announcement.

The removal of the condition will facilitate access to the drug for a wider patient population, Wockhardt said. The company has deployed a field force for Miqnaf and reported increasing clinical acceptance, citing its pathogen coverage and shorter therapy.

Wockhardt plans to file for an additional indication for Miqnaf for upper respiratory tract infections in the third or fourth quarter of FY27.

The announcement comes as the pharmaceutical company reported a 24% year-on-year increase in consolidated revenue to Rs 969 crore in the second quarter of FY27, compared with Rs 782 crore in the year-ago quarter.

Consolidated profit after tax (PAT), however, declined to Rs 73 crore from Rs 82 crore in the corresponding quarter last year. Earnings before interest, taxes, depreciation and amortisation (EBITDA) stood at Rs 165 crore, compared with Rs 160 crore a year ago. EBITDA, excluding pre-launch expenses for Zaynich, was Rs 201 crore.

Live Events

Zaynich receives US FDA approval

Wockhardt also highlighted the US Food and Drug Administration's approval of its novel antibiotic Zaynich on May 29 for complicated urinary tract infections (cUTI), including pyelonephritis.

The company said Zaynich is the first drug discovered and developed in India to receive US FDA approval.

The European Medicines Agency is reviewing the drug's dossier for proposed indications including cUTI, complicated intra-abdominal infections, hospital-acquired and ventilator-associated pneumonia, and bloodstream infections.

In India, the Central Drugs Standard Control Organisation granted manufacturing and marketing approval for Zaynich on August 25, 2026.

Wockhardt said five of its novel antibiotics, Emrok, Emrok O, Miqnaf, Zaynich and Foviscu, have completed Phase 3 trials.

Biotech business records growth

Wockhardt's biotechnology operations reported revenue of Rs 252 crore in the second quarter, up 68% year-on-year. Revenue for the first half of FY27 rose 87% to Rs 487 crore.

The company said its emerging-market biotechnology business recorded around 110% growth in the first half, with opportunities and partnerships across Brazil, Thailand, Egypt, Algeria and Latin America. Its India biotechnology business recorded double-digit growth.

The India branded business reported second-quarter revenue of Rs 146 crore, up 8%, while first-half revenue rose 14% to Rs 303 crore.

Revenue from emerging markets increased 52% to Rs 310 crore in the second quarter and 54% to Rs 574 crore in the first half.

During the quarter, Wockhardt reported 24 filings, 18 approvals and 11 launches in its international business. Its biosimilar business recorded two filings and four approvals, while its new chemical entity (NCE) business reported one filing and two approvals.

The company also said it filed seven patents and received six patent grants during the quarter. Its cumulative patent filings stood at 3,298, with 865 patents granted.
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onwockhardtWockhardtMiqnafZaynichcomplicated urinary tract infectionsantibioticbiotechnologyclinical acceptancePhase 3 trialsDCGI

(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)

...moreless
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onwockhardtWockhardtMiqnafZaynichcomplicated urinary tract infectionsantibioticbiotechnologyclinical acceptancePhase 3 trialsDCGI

(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)

...morelessContinue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories
& personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions &
in-depth stock reportsSubscribe NowET

Unlock Access to All Exclusives with ETPrime FREE TRIAL

15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers

Trial offer expiring in00 : 05 : 00

I'd rather pay ₹2599 now

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Prime Account Detected!

It seems like you're already an ETPrime member with

Login using your ET Prime credentials to enjoy all member benefits

Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.

Unlock ETPrime's Exclusive Stories Today!

Big Price Drop! Flat 40% Off

Student Only OfferAlready a Member? Sign In nowAlready a Member? Sign In nowAlready a Member? Sign In now

Offer Exclusively For You

Save up to Rs. 700/-

ON ET PRIME MEMBERSHIP

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get Flat 40% Off

Then ₹ 1749 for 1 year

Avail Offer

Offer Exclusively For You

ET Prime at ₹ 49 for 1 month

Then ₹ 1749 for 1 year

Avail Offer

Special Offer

Get flat 40% off on ETPrime

Avail OfferAvail OfferClaim NowAlready a Member? Sign In now

Need Assistance?

Connect with an ETPrime expert for personalized support and guidance

+91 9484700004'; }); } if(listing) { var h3 = "You tried reading " + listArr.length + " locked stories in the past " + threshold + " days.", h4 = "Become an ET Prime member and don't miss out on these exclusive stories."; var html = '

' + h3 + '

' + h4 + '

' + listing + '

'; $('#paidSCWidget').html(html); var callback = $('#paidSCWidget').attr('data-callback'); if(callback && window[callback]) { window[callback](); } customDimension.dimension72 += ' | Shown SYFT no Trial_With Missed Paywalled Articles Collection'; } else { _processNormal() } } }); } else { _processNormal(); } } catch (e) { _processNormal(); } }, function () { _processNormal(); }); //console.log('storyCollectionLoad', $); }

What’s Included with

ETPrime Membership

1Exclusive Insights That Matter

Uncover the truth with our investigative stories

Make strategic moves using the real-world case studies

Read industry-specific stories to identify emerging trends

Spot opportunities with
in-depth insights that matter

• Trump temper on H-1B visas is forcing Indians to do these things to stay put in US

  What Adani’s US indictment means for India Inc’s overseas fundraising

• Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.

  Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?

• Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?

  The problem with lab grown diamonds

• Why a falling rupee is a better option for the economy

  A list of top 20 momentum stocks that have delivered massive returns in one year

2Invest Wisely With Smart Market Tools & Investment Ideas

Alpha Trade

Get daily trade ideas from SEBI-registered research analysts.

Investment Ideas

Grow your wealth with stock ideas & sectoral trends.

Stock Reports Plus

All-in-one stock research with Stock Score, peer comparison & key signals.

BigBull Portfolio

Get to know where the market bulls are investing to identify the right stocks.

Stock Analyzer

Check the score based on the company's fundamentals, solvency, growth, risk & ownership to decide the right stocks.

Market Mood

Analyze the market sentiments & identify the trend reversal for strategic decisions.

Stock Talk Live at 9 AM Daily

Ask your stock queries & get assured replies by ET appointed, SEBI registered experts.

3Stay informed anytime, anywhere with ET ePaper

ePaper - Print View

Read the PDF version of ET newspaper. Download & access it offline anytime.

ePaper - Digital View

Read your daily newspaper in Digital View & get it delivered to your inbox everyday.

Wealth Edition

Manage your money efficiently with this weekly money management guide.

TOI ePaper

Read the PDF version of TOI newspaper. Download & access it offline anytime.

Deep Explainers

Explore the In-depth explanation of complex topics for everyday life decisions.

Health+ Stories

Get fitter with daily health insights committed to your well-being.

Personal Finance+ Stories

Manage your wealth better with in-depth insights & updates on finance.

5Enjoy Complimentary Subscriptions From Top Brands

Stream new documentaries from all across the world every day.

Stories you might be interested in